|
Video: What is a Stock Split?
|
|
Eagle Pharmaceuticals is an integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. Co.'s products and product portfolio include: BARHEMSYS® (amisulpride for injection), which is for the treatment of postoperative nausea and vomiting; BYFAVO® (remimazolam for injection), which is indicated for the induction and maintenance of procedural sedation; bendamustine ready-to-dilute (RTD) 500ml solution, infused bendamustine RTD, and bendamustine RTD and infused RTD in Japan for Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma; Ryanodex® (dantrolene sodium) for Malignant Hyperthermia; and EA-114 (fulvestrant) for breast cancer. According to our Eagle Pharmaceuticals stock split history records, Eagle Pharmaceuticals has had 0 splits. | |
|
Eagle Pharmaceuticals (EGRX) has 0 splits in our Eagle Pharmaceuticals stock split history database.
Looking at the Eagle Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Eagle Pharmaceuticals shares, starting with a $10,000 purchase of EGRX, presented on a split-history-adjusted basis factoring in the complete Eagle Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$12.75 |
|
End price/share: |
$5.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-60.71% |
|
Average Annual Total Return: |
-8.92% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,929.54 |
|
Years: |
10.00 |
|
|
|
|
|